Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
To investigate the therapeutic effect and safety of celecoxib adding on doxazosin and the
potential predictive value of the absence of prostate cancer in the treatment of patients
with LUTS/BPH and an elevated serum PSA level.
Patients who meet all eligible requirements for entry into the study will be randomized into
one of the two treatment groups for 3 months in 2:1 ratio as shown below:
1. Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
2. Doxazosin 4mg every day (QD)